Rynkiewicz
David E. Rynkiewicz, Auburn, NY US
Patent application number | Description | Published |
---|---|---|
20110246565 | EXTENSIBILITY FOR MANIPULATION OF MEDICAL DATA - A method for extending a functionality of a computing device programmed to obtain physiological measurements from a patient includes: registering, at the computing device, a plug-in module, the plug-in module providing additional functionality for the computing device; using the plug-in module to communicate with a medical device; commanding the medical device to obtain physiological information from a patient; receiving data associated with the physiological information from the medical device; and transferring the data to a central repository. | 10-06-2011 |
20140040429 | Extensibility for Manipulation of Medical Data - A method for extending a functionality of a computing device programmed to obtain physiological measurements from a patient includes: registering, at the computing device, a plug-in module, the plug-in module providing additional functionality for the computing device; using the plug-in module to communicate with a medical device; commanding the medical device to obtain physiological information from a patient; receiving data associated with the physiological information from the medical device; and transferring the data to a central repository. | 02-06-2014 |
Michael Rynkiewicz, Boston, MA US
Patent application number | Description | Published |
---|---|---|
20090130102 | METHODS FOR HUMANIZING ANTIBODIES AND HUMANIZED ANTIBODIES MADE THEREBY - Disclosed herein is the use of three-dimensional structure information to guide the process of modifying antibodies with amino acids from one or more templates or surrogates such that the antigen binding properties of the parent antibody are maintained and the immunogenicity potential is reduced when administered as a therapeutic in humans. | 05-21-2009 |
Michael Rynkiewicz, Beijing CN
Patent application number | Description | Published |
---|---|---|
20120321643 | ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES AND USES THEREOF - The present invention discloses humanized anti-epidermal growth factor receptor antibodies, which have favorable binding activity (the binding affinity being 6.13×10 | 12-20-2012 |
20130022624 | ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES AND USES THEREOF - The present invention discloses humanized anti-epidermal growth factor receptor antibodies, which have favorable binding activity (the binding affinity being 5.09×10 | 01-24-2013 |
Michael Rynkiewicz, Newton, MA US
Patent application number | Description | Published |
---|---|---|
20130330362 | HUMANIZED ANTI-EGFR ANTIBODY L4-H3 AND CODING GENE THEREOF - A humanized anti-EGFR antibody L4-H3 and gene encoding the antibody are disclosed. The antibody is composed of a heavy chain and a light chain. The amino acid sequence of the heavy chain variable region is shown as positions 1-145 of SEQ ID NO: 3, the heavy chain constant region is the heavy chain constant region of the human antibody IgG1, and the amino acid sequence of the light chain is shown as SEQ ID NO: 1. | 12-12-2013 |
Michael J. Rynkiewicz, Boston, MA US
Patent application number | Description | Published |
---|---|---|
20090143351 | SUBSTITUTED AZETIDINONES - Compounds are provided which have the structure | 06-04-2009 |
20100144698 | SUBSTITUTED AZETIDINONES - Compounds are provided which have the structure | 06-10-2010 |
Robert Rynkiewicz, Starogard Gdanski PL
Patent application number | Description | Published |
---|---|---|
20090281320 | PROCESS FOR THE PREPARATION OF [1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE] BISPHOSPHONIC ACID AND HEMIPENTAHYDRATE MONOSODIUM SALT THEREOF - The invention relates to a novel process for the preparation of [1-hydroxy-2-(3-pyridinyl)ethylidene] bisphosphonic acid and hemipentahydrate monosodium salt thereof comprising (a) reacting an aqueous solution of 3-pyridyl acetic acid hydrochloride with phosphorus trichloride; (b) removing unreacted phosphorus trichloride; (c) adding water and hydrolyzing; (d) isolating crystalline [1-hydroxy-2-(3-pyridinyl)ethylidene] bisphosphonic acid; (e) suspending said crystalline [1-hydroxy-2-(3-pyridinyl)ethylidene] bisphosphonic acid in water; (f) adding sodium hydroxide, filtering off, and washing; and (g) drying obtained hemipentahydrate monosodium salt of 1-hydroxy-2-(3-pyridinyl)ethylidene] bisphosphonic acid. | 11-12-2009 |
20100069641 | PROCESS FOR THE PREPARATION OF SODIUM SALT OF 1-(((1(R)-(3-(2-(7-CHLORO-2-QUINOLINYL)-ETHENYL)PHENYL)-3-(2-(1-HYDROXY-1- -METHYLETHYL)PHENYL)PROPYL)SULFANYL)METHYL)CYCLOPROPANEACETIC ACID - A novel process for the preparation of a sodium salt of 1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)-ethenyl)phenyl)-3-(2-(1-hydroxy-1-methyl-ethyl)phenyl)propyl)sulfanyl)methyl)cyclopropaneacetic acid, comprising: a) reacting a compound of Formula 1 with methanesulfonyl chloride in the presence of a tertiary amine to yield a crude solution of a compound of Formula 2; b) filtering the crude solution of compound of Formula 2 obtained in a) to remove solid amine hydrochloride, reacting the filtrate without isolation or further purification with a compound of Formula 3, and isolating 1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)-ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)sulfanyl)methyl)cyclopropaneacetic acid; c) reacting the 1-(((1(R)-(3-(2-(7-chloro-2-quinolinyl)-ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)sulfanyl)methyl)cyclopropaneacetic acid isolated in b) with tert-butylamine to yield a compound of formula 4; d) isolating and purifying the compound of formula 4; and e) converting the compound of formula 4 to a compound of formula 5. | 03-18-2010 |
20120116092 | PROCESS FOR THE PREPARATION OF [1-HYDROXY-2-(1H-IMIDAZOL-1-YL)- ETHYLIDENE] BISPHOSPHONIC ACID - A process for the preparation of [1-hydroxy-2-(1H-imidazol-1-yl)-ethylidene]bisphosphonic acid consists of the reaction of aqueous solution of 1H-imidazole-1-acetic acid hydrochloride with phosphorus trichloride followed by removal of the excess of phosphorus trichloride, addition of water and hydrolysis of the reaction products. In order to isolate the product the post-reaction mixture is filtered and the anti-solvent is added to the aqueous filtrate in order to crystallize out [1-hydroxy-2-(1H-imidazol-1-yl)-ethylidene]bisphosphonic acid monohydrate. | 05-10-2012 |